Literature DB >> 15122522

Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.

Hasan S Jafri1, Susana Chavez-Bueno, Asuncion Mejias, Ana M Gomez, Ana M Rios, Shahryar S Nassi, Munira Yusuf, Payal Kapur, Robert D Hardy, Jeanine Hatfield, Beverly B Rogers, Karen Krisher, Octavio Ramilo.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) infection is associated with acute morbidity (e.g., pneumonia and airway obstruction [AO]) and long-term complications (e.g., airway hyperresponsiveness [AHR]). We present a comprehensive evaluation of the acute and chronic phases of RSV respiratory tract infection, using a mouse model.
METHODS: BALB/c mice were inoculated with RSV and monitored for 154 days. RSV loads and cytokines were measured in bronchoalveolar lavage (BAL) samples. Pneumonia severity was assessed using a standard histopathologic score, and pulmonary function was determined by plethysmography.
RESULTS: RSV-infected mice exhibited viral replication that peaked on day 4-5 and became undetectable by day 7. These mice developed acute pneumonia (peak days, 4-5) and chronic pulmonary inflammatory infiltrates that lasted up to 154 days after inoculation. BAL concentrations of tumor necrosis factor- alpha, interleukin (IL)-6, interferon- gamma, IL-4, IL-10, KC (an IL-8 homologue), MIG (CXCL9), RANTES, macrophage inflammatory protein-1 alpha, and eotaxin were significantly higher in RSV-infected mice than in control mice. RSV-infected mice developed acute AO during the first week of infection that persisted for 42 days. RSV-infected mice also showed significant AHR in response to methacholine up to 154 days.
CONCLUSION: This model provides a means to investigate the immunopathogenesis of RSV infection and its association with reactive airway disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122522     DOI: 10.1086/386372

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  79 in total

1.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

2.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection.

Authors:  Marie-Eve Hamelin; Gregory A Prince; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Dipeptidyl peptidase I-dependent neutrophil recruitment modulates the inflammatory response to Sendai virus infection.

Authors:  Antonina M Akk; Pamela M Simmons; Happy W Chan; Eugene Agapov; Michael J Holtzman; Mitchell H Grayson; Christine T N Pham
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

5.  Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

Authors:  Chadi M El Saleeby; Andy J Bush; Lisa M Harrison; Jody A Aitken; John P Devincenzo
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

Review 6.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

7.  Disruption of the airway epithelial barrier in a murine model of respiratory syncytial virus infection.

Authors:  Carrie C Smallcombe; Debra T Linfield; Terri J Harford; Vladimir Bokun; Andrei I Ivanov; Giovanni Piedimonte; Fariba Rezaee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-11-29       Impact factor: 5.464

8.  Age-associated aggravation of clinical disease after primary metapneumovirus infection of BALB/c mice.

Authors:  M Darniot; C Pitoiset; T Petrella; S Aho; P Pothier; C Manoha
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

9.  T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection.

Authors:  Deepthi Kolli; Efthalia L Bataki; Leanne Spetch; Antonieta Guerrero-Plata; Alan M Jewell; Pedro A Piedra; Gregg N Milligan; Roberto P Garofalo; Antonella Casola
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model.

Authors:  Dora Estripeaut; Juan Pablo Torres; Cynthia S Somers; Claudia Tagliabue; Shama Khokhar; Vijay G Bhoj; Steve M Grube; Aneta Wozniakowski; Ana M Gomez; Octavio Ramilo; Hasan S Jafri; Asuncion Mejias
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.